Vladislav Yu. Kirsanov

Vladislav Yu. Kirsanov

Auto-generated profile, based on publicly available information

Vladislav Yu. Kirsanov

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2020 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
IVIrina V. Visotskaya
Irina V. Visotskaya
VLVictor P. Letyagin
Victor P. Letyagin
IVIgor K. Vorotnikov
Igor K. Vorotnikov
EKElena A. Kim
Elena A. Kim
VKVladislav Yu. Kirsanov
Vladislav Yu. Kirsanov
SPSvetlana B. Polikarpova
Svetlana B. Polikarpova
Diseases of the mammary glands (usually benign) have the incidence of 5–12% in the structure of children diseases. Breast cancer is extremely rare (less than 1% of all breast diseases). This review contains actual data on the most common focal pathology of mammary glands in teenage girls such as: focal hyperplasia, cysts and breast fibroepithelial tumors. Clinical manifestations, morphological picture and diagnostics are described. Main approaches to treatment of patients with focal pathology of mammary glands are defined. The presented data is crucial for timely diagnosis of focal pathology of mammary glands, selection of examination tactics, management and necessary measures for oncological diseases prevention in children.

2 May 2024 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
AAA. Yu. Anokhin
A. Yu. Anokhin
PKP. V. Kononets
P. V. Kononets
DKD. Yu. Kanner
D. Yu. Kanner
DSD. L. Stroyakovsky
D. L. Stroyakovsky
ASA. O. Shveykin
A. O. Shveykin
ATA. S. Tyulandina
A. S. Tyulandina
Background. The established approach notably improving the therapeutic outcomes for locally advanced gastric cancer and gastroesophageal junction cancer, presently entails the amalgamation of perioperative chemotherapy aligned with the FLOT protocol and surgical intervention. However, this approach harbors limitations, as only half of the patient cohort successfully completes the entire prescribed course of drug therapy. The potential solution to this problem lies in the complete transfer of the chemotherapy volume to the preoperative period and the execution of total neoadjuvant chemotherapy with FLOT regimen.Aim. Aim is to conduct a comparative assessment of the efficacy and safety between total neoadjuvant and perioperative chemotherapy with FLOT regimen for patients with locally advanced gastric cancer and gastroesophageal junction cancer.Materials and methods. In a retrospective study we enrolled patients with histologically confirmed locally advanced gastric cancer and gastroesophageal junction cancer meeting clinical stage criteria T2–4 and N0–3, without of distant metastases, treated between 2014 and 2020 at Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation and Moscow City Oncologic Hospital No. 62 Department of Healthcare of Moscow. Participants in the control group underwent 8 courses of perioperative chemotherapy (4 preoperatively and 4 postoperatively), while those in the experimental group received 8 courses of total neoadjuvant chemotherapy. Both groups received drug therapy according to the FLOT protocol: 5-fluorouracil 2600 mg/m2 , intravenous drip, over 24 hours, leucovorin 200 mg/m2 , intravenous drip, oxaliplatin 85 mg/m2 , intravenous drip, docetaxel 50 mg/m2 , intravenous drip, on day 1, with a 14-day intercourse interval. The primary endpoint was one-year progression-free survival.Results. In the study included 187 patients. Participants were divided into two groups: 95 in the total neoadjuvant chemotherapy group and 92 in the perioperative chemotherapy group. The one-year progression-free survival was higher in the total neoadjuvant chemotherapy group at 79 %, compared to 68 % in the perioperative chemotherapy group (HR 0.54, 95 % confidence interval 0.32–0.9, p = 0.02). Median disease-free survival was 27.2 and 19.5 months in the neoadjuvant and perioperative chemotherapy groups, respectively. The tolerability of the entire planned drug treatment regimen was superior in the total neoadjuvant chemotherapy group, reaching 88.4 %, as opposed to 57.6 % in the perioperative chemotherapy group (p = 0.0001).Conclusion. Among patients with locally advanced gastric cancer and gastroesophageal junction cancer, the application of total neoadjuvant chemotherapy according to the FLOT protocol, administered over 8 courses, demonstrated enhanced one-year progression-free survival and improved tolerability of the entire planned treatment regimen.

18 September 2021 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
IVI. V. Vуsotskaya
I. V. Vуsotskaya
IGI. A. Gladilina
I. A. Gladilina
VKV. Yu. Kirsanov
V. Yu. Kirsanov
НПН. В. Понедельникова
Н. В. Понедельникова
EKE. A. Kim
E. A. Kim
VPValeriy Ponomarev
Valeriy Ponomarev
The article deals with a peculiar group of breast diseases, which belongs to the B3 category according to the BI-RADS classification, the so-called lesions with undefined malignant potential. The basic information concerning their biological behavior and modern tactical approaches to the management of patients with similar changes in the mammary gland are presented. The possibility of conservative management, as well as the minimization of surgical aid, in cases of indications for it, up to vacuum aspiration biopsy is being considered. In addition, the significance of these diseases for the subsequent development of pre-invasive and infiltrative cancer is discussed.

2 December 2022 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
IVI. V. Vysotskaya
I. V. Vysotskaya
EKE. A. Kim
E. A. Kim
VKV. Yu. Kirsanov
V. Yu. Kirsanov
SPS. B. Polikarpova
S. B. Polikarpova
VPValeriy Ponomarev
Valeriy Ponomarev
The article presents updated data concerning the molecular mechanisms of influence of the well-known in clinical practice drug Mastodynon. The paper provides evidence of a significant effect of the compounds containing in its composition on the cell lines of a number of malignant neoplasms: breast cancer, hepatocellular carcinoma, leukemia and others. The data obtained are extremely attractive in the perspective of using the drug as a preventive agent.

6 September 2019 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
IVI. V. Vуsotskaya
I. V. Vуsotskaya
VLV. P. Letyagin
V. P. Letyagin
IVI. K. Vorotnikov
I. K. Vorotnikov
VKV. U. Kirsanov
V. U. Kirsanov
IGI. A. Gladilina
I. A. Gladilina
EKE. A. Kim
E. A. Kim
The research provided includes analysis of the current state of the problem on the use of oral contraceptives and menopausal hormone therapy. These therapeutic options were evaluated in terms of their importance for the risk of breast cancer. The possibility of using these drugs in a cohort of high-risk patients (women with family history of breast cancer) and in the group of patients with benign pathology was analyzed as well. Modern trends of menopausal hormone therapy prescription in different clinical situations were determined.

24 July 2020 in Head and Neck Tumors (HNT)
Verified
Journal Article
Open access
PDF file
NSN. V. Sevian
N. V. Sevian
ABA. Kh. Bekyashev
A. Kh. Bekyashev
EPEvgeny Prozorenko
Evgeny Prozorenko
NKN. A. Kozlov
N. A. Kozlov
DNDavid Naskhletashvili
David Naskhletashvili
OMO. A. Malikhova
O. A. Malikhova
Esophageal cancer spreads locally via the circulatory and lymphatic systems and can, extremely rarely, form brain metastases. The development of intracranial metastases is a long-term adverse event indicating poor prognosis. In this paper, we present a case of esophageal cancer with a brain metastasis in a patient who received combination therapy and demonstrated long-term progression-free survival.